1. ProEx C as Diagnostic Marker for Detection of Urothelial Carcinoma in Urinary Samples: A Review.
- Author
-
Botti G, Malzone MG, La Mantia E, Montanari M, Vanacore D, Rossetti S, Quagliariello V, Cavaliere C, Di Franco R, Castaldo L, Ametrano G, Cappuccio F, Romano FJ, Piscitelli R, Pepe MF, D'Aniello C, and Facchini G
- Subjects
- Antibodies immunology, Biomarkers, Tumor immunology, Cytodiagnosis, DNA Topoisomerases, Type II immunology, Female, Humans, Minichromosome Maintenance Complex Component 2 immunology, Poly-ADP-Ribose Binding Proteins immunology, Prognosis, Reagent Kits, Diagnostic, Urologic Neoplasms genetics, Urologic Neoplasms pathology, Vaginal Smears, Biomarkers, Tumor genetics, DNA Topoisomerases, Type II genetics, Minichromosome Maintenance Complex Component 2 genetics, Poly-ADP-Ribose Binding Proteins genetics, Urologic Neoplasms diagnosis
- Abstract
The gold standard for the detection of urothelial carcinoma is represented by urethro-cystoscopy and biopsy. Both procedures are invasive and expensive and therefore cytology is often used as first approach to investigate on a possible neoplasia, being a safe and cost-effective diagnostic modality of evaluation. Because cytology alone is not highly sensitive for detection of low grade urothelial carcinoma and recurrence of the disease, several adjunct markers and urine based tests for urothelial carcinoma have been developed, which can help in the final diagnosis. In particular, ProEx C is an immunohistochemical cocktail containing antibodies direct against topoisomerase IIα (TOP2A) and minichromosome maintenance 2 (MCM2) proteins. It proved to be a valid biomarker especially in detecting squamous intraepithelial lesions in cervical liquid-based samples and in discerning these lesions from their mimickers, as well as in ovarian, endometrial, vulvar, primary and metastatic melanomas, breast, pancreatic and renal cell carcinomas. This brief review covers the effective utility of ProEx C as adjunct tool in assessing the urothelial lesions in urine cytology, also providing prognostic and therapeutic information to help in clinical decisions., Competing Interests: Competing Interests: The authors have declared that no competing interest exists.
- Published
- 2017
- Full Text
- View/download PDF